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Abstract 1 
Objectives  2 
To develop prognostic models for risk of a breakthrough seizure, risk of seizure recurrence 3 
after a breakthrough seizure, and likelihood of achieving 12-month remission following a 4 
breakthrough seizure. A breakthrough seizure is one that occurs following at least 12 months 5 
remission whilst on treatment. 6 
Methods  7 
We analysed data from the SANAD study. This long-term randomised trial compared 8 
treatments for participants with newly diagnosed epilepsy. Multivariable Cox models 9 
investigated how clinical factors affect the probability of each outcome. Best fitting 10 
multivariable models were produced with variable reduction by Akaike’s Information 11 
Criterion. Risks associated with combinations of risk factors were calculated from each 12 
multivariable model.  13 
Results 14 
Significant factors in the multivariable model for risk of a breakthrough seizure following 12-15 
month remission were number of tonic-clonic seizures by achievement of 12-month remission, 16 
time taken to achieve 12-month remission, and neurological insult. Significant factors in the 17 
model for risk of seizure recurrence following a breakthrough seizure were total number of 18 
drugs attempted to achieve 12-month remission, time to achieve 12-month remission prior to 19 
breakthrough seizure, and breakthrough seizure treatment decision. Significant factors in the 20 
model for likelihood of achieving 12-month remission after a breakthrough seizure were 21 
gender, age at breakthrough seizure, time to achieve 12-month remission prior to breakthrough, 22 
and breakthrough seizure treatment decision. 23 
Conclusions  24 
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This is the first analysis to consider risk of a breakthrough seizure and subsequent outcomes. 1 
The described models can be used to identify people most likely to have a breakthrough seizure, 2 
a seizure recurrence following a breakthrough seizure, and to achieve 12-month remission 3 
following a breakthrough seizure. The results suggest that focussing on achieving 12-month 4 
remission swiftly represents the best therapeutic aim to reduce the risk of a breakthrough 5 
seizure and subsequent negative outcomes.  This will aid individual patient risk stratification 6 
and the design of future epilepsy trials. 7 
 8 
Introduction 9 
Epilepsy is one of the most common serious neurological disorders worldwide, affecting 10 
approximately 50 million people. Estimates suggest that 60 to 70% of people with epilepsy 11 
will achieve a remission from seizures.[1] However, up to 37% of these people may proceed 12 
to have a breakthrough seizure.[2] A breakthrough seizure is defined as an epileptic seizure 13 
which occurs despite the use of antiepileptic drugs that have otherwise successfully prevented 14 
seizures in the patient.[3]  15 
Breakthrough seizures might occur for a number of reasons – those inherent to the person’s 16 
epilepsy, or the natural history of the condition. Inherent factors include the dose of 17 
antiepileptic drug treatment being insufficient to reduce the seizure rate to zero, missed doses 18 
of medication, or provoking factors such as emotional stress, sleep deprivation, alcohol or other 19 
recreational drugs, and TV or video games.[4, 5] For some people, the natural history is to 20 
develop treatment refractoriness following a period of remission, presumably due to on-going 21 
epileptogenic processes.[6-8] Frequently, the cause of a breakthrough seizure may not be 22 
identified.  23 
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Some argue that breakthrough seizures are more dangerous than non-breakthrough seizures as 1 
they are unexpected by the patient, and therefore, the person may not take appropriate 2 
precautions.[9] Breakthrough seizures can have severe clinical consequences for the person – 3 
they may be admitted to hospital either as a result of the seizure, or because of injuries sustained 4 
during the seizure. Breakthrough seizures can take the form of status epilepticus which is 5 
associated with elevated morbidity, and potentially mortality.[10, 11] 6 
Despite the fact that breakthrough seizures are commonly seen in clinical practice, very few 7 
publications have examined factors associated with a breakthrough seizure and outcomes 8 
following such a seizure. Two papers consider breakthrough seizures among people with 9 
epilepsy in developing countries,[12, 13] however similar papers for people in developed 10 
countries are lacking. It is clearly important that we are able to stratify for outcome following 11 
a breakthrough seizure to identify those likely to regain seizure control, and those with a worse 12 
prognosis who may need more intensive management. This analysis investigates the risk of a 13 
first breakthrough seizure following the first period of 12-month remission, the likelihood of a 14 
seizure recurrence following a breakthrough seizure, and the chance of achieving a period of 15 
12-month remission following a breakthrough seizure. Included participants were those 16 
recruited to the UK-based multi-centre Standard versus New Antiepileptic Drug (SANAD) 17 
study. 18 
Methods 19 
Participants 20 
Full details of the SANAD study have been published elsewhere.[14, 15] In brief, people were 21 
eligible for inclusion if they had a history of at least two clinically definite unprovoked epileptic 22 
seizures in the last year, and they were aged at least five years. Participants were recruited to 23 
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Arm A if the recruiting clinician considered carbamazepine to be the standard treatment option. 1 
Between December 1st 1999 and June 1st 2001 participants were randomised in a ratio of 1:1:1:1 2 
to carbamazepine, gabapentin, lamotrigine, or topiramate. From 1st June 2001 to 31st August 3 
2004 an oxcarbazepine group was added to the trial. 4 
People were recruited into Arm B if the recruiting clinician regarded valproate the standard 5 
treatment option. Participants were randomised in a 1:1:1 ratio to valproate, lamotrigine or 6 
topiramate between January 12th 1999 and August 31st 2004.  7 
The two primary outcomes in SANAD were time to treatment failure from randomisation and 8 
time to the first period of 12-month remission from seizures following randomisation. In this 9 
paper the SANAD Arm A and SANAD Arm B datasets have been combined in order to 10 
undertake prognostic modelling, stratifying by study arm. In the original publications trial arms 11 
were analysed and reported separately, as the primary purpose was to compare the effectiveness 12 
of new antiepileptic drugs with the standard treatments. Here the purpose is different, the aim 13 
being to assess the risk of a breakthrough seizure, or outcome following a breakthrough seizure, 14 
irrespective of the specific drug that the patient was on at randomisation, or the subsequent 15 
choice of treatment. 16 
Relevant participants for these analyses were those who had achieved their first period of 12-17 
month remission whilst on treatment. No age or other restrictions were imposed.  18 
SANAD received appropriate multicentre and local ethics and research committee approvals, 19 
and was managed according to the Medical Research Council’s Good Clinical Practice 20 
Guidelines. Patients gave informed written consent to inclusion and to long-term follow-up. 21 
SANAD is registered as an International Standard Randomised Controlled Trial, number 22 
ISRCTN38354748.  23 
 24 
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Statistical Analysis 1 
The three outcomes of interest were (1) first breakthrough seizure following first period of 12-2 
month remission, (2) seizure recurrence following a first breakthrough seizure, and (3) 12-3 
month remission following a first breakthrough seizure. The risk estimates were all conditional 4 
on achieving a first period of 12-month remission.  5 
Each outcome was analysed using a Cox proportional hazard model. For the risk of 6 
breakthrough seizure analysis, time zero was the time at which a 12-month period of seizure 7 
freedom was achieved. For example, if a participant had 23 months of seizure freedom 8 
immediately after randomisation followed by a seizure, their start time for the analysis of 9 
breakthrough seizure was 12 months, and their time to breakthrough seizure would be 11 10 
months. For the other two outcomes, time zero was the date of the first breakthrough seizure 11 
following first period of 12-month remission.  12 
Variables associated with a higher risk of seizure recurrence were determined univariably and 13 
after adjusting for multiple variables using log-rank tests and Cox proportional hazards 14 
modelling methods. Best fitting, parsimonious, multivariable models were produced with 15 
variable reduction by Akaike’s Information Criterion (AIC) – the model with the smallest AIC 16 
was identified as the parsimonious model.[16] Risk estimates for combinations of clinical risk 17 
factors were calculated from each multivariable model.[17] In particular, the baseline survivor 18 
function was estimated for each model, and then raised to a suitable power based on the 19 
combination of risk factors being considered.   20 
Schöenfeld residual plots [18] and incorporation of time-dependent covariate effects were used 21 
to investigate the proportional hazards assumption. The predictive accuracy of the models was 22 
assessed using the c-statistic.[19]  Analyses were performed using R version 3.2.3,[20] and 23 
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significance was set at the 5% level.  Computer code for all analyses are available in S1, S2 1 
and S3 Files. 2 
The list of potential prognostic factors for all three outcomes included: gender, febrile seizure 3 
history, first degree relative with epilepsy, neurological insult (learning difficulty or 4 
neurological deficit defined as localising neurological signs resulting in functional 5 
impairment), seizure type, epilepsy type, baseline electroencephalogram (EEG) result, baseline 6 
computerised tomography (CT) or magnetic resonance imaging (MRI) result, total number of 7 
treatments attempted to achieve first period of 12-month remission (one, or more than one), 8 
and time to achieve 12-month remission from randomisation. Additionally, total number of 9 
tonic-clonic seizures ever up until achievement of 12-month remission (classified according to 10 
the International League Against Epilepsy seizure classification[21]), and age at achievement 11 
of 12-month remission were considered in the risk of breakthrough seizure analysis. Total 12 
number of tonic-clonic seizures ever until breakthrough seizure, age at breakthrough seizure, 13 
and breakthrough seizure treatment decision (leave as it is, increase, or decrease) were 14 
additionally included in the analysis of seizure recurrence following a first breakthrough 15 
seizure, and 12-month remission following a first breakthrough seizure. 16 
EEG was classified as normal, not done, non-specific abnormality, or epileptiform abnormality 17 
(focal or generalized spikes or spike and slow wave activity). Epilepsy type was classified as 18 
focal, generalised, or unclassified with the unclassified category being used when there was 19 
uncertainty between focal onset and generalised onset seizures. 20 
Continuous variables (time to 12-month remission, total number of tonic-clonic seizures and 21 
age) were investigated using log and fractional polynomial transformations.[22-25] Results for 22 
the continuous variables are presented as post-hoc defined categorical variables with categories 23 
chosen according to knot positions for a spline model fit to the data.[26]  24 
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Results 1 
Fig 1 illustrates the disposition of the 2627 participants recruited into both Arm A and Arm B 2 
of SANAD. It also identifies participants relevant to each of the outcomes in this analysis. 3 
Fig 1: Trial Profile 4 
Risk of a breakthrough seizure 5 
Table 1 summarises the participant demographics for those achieving a first period of 12 month 6 
remission on treatment who were therefore at risk of a first breakthrough seizure. At 2 years 7 
following a remission, the overall risk of a breakthrough seizure is 37% (Fig 2). Of the 1593 8 
participants included in this analysis, 536 had a first breakthrough seizure with median time to 9 
first breakthrough seizure 0.7 years from starting treatment (interquartile range (IQR) 0.2-1.2 10 
years). Additionally, the median follow-up time from achievement of 12-month remission to 11 
date of last follow-up was 2.0 years (IQR 1.0-3.3 years). 12 
Fig 2: Risk of a first breakthrough seizure following a period of at least 12 months 13 
remission from seizures whilst on treatment 14 
Table 1: Participant demographics for those at risk of a first breakthrough seizure, n (%) 15 
unless otherwise stated 16 
Characteristic 
Arm A 
(n=1067) 
Arm B 
(n=526) 
Total 
(n=1593) 
Male 609 (57) 314 (60) 923 (58) 
Febrile Seizure History 61 (6) 44 (8) 105 (7) 
Epilepsy in first degree relative  111 (10) 89 (17) 200 (13) 
Neurological insult 104 (10) 52 (10) 156 (10) 
Seizures          
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Simple or Complex Partial with Secondary Generalised 
Seizures 
597 (56) 15 (3) 622 (39) 
Simple or Complex Partial only 328 (31) 25 (4) 343 (22) 
Generalised tonic-clonic seizures only 15 (1) 154 (29) 169 (11) 
Absence seizures 2 (0) 82 (16) 84 (5) 
Myoclonic or absence seizures with tonic- clonic seizures 3 (0) 106 (20) 109 (7) 
Tonic-clonic seizures, uncertain if focal or generalised 113 (11) 114 (22) 227 (14) 
Other 9 (1) 30 (6) 39 (2) 
Epilepsy type    
Partial 929 (87) 40 (8) 969 (61) 
Generalised 21 (2) 357 (68) 378 (24) 
Unclassified 117 (11) 129 (24) 246 (15) 
EEG results    
Normal 472 (44) 129 (25) 601 (38) 
Non-specific Abnormality 180 (17) 55 (10) 235 (15) 
Epileptiform Abnormality 328 (31) 321 (61) 649 (40) 
Not donea 87 (8) 21 (4) 108 (7) 
CT/MRI scan results    
Normal 639 (60) 233 (44) 872 (55) 
Abnormal 262 (25) 30 (6) 292 (18) 
Not doneb 166 (15) 263 (50) 429 (27) 
Drugs attempted to achieve 12-month remission    
One 805 (75) 397 (75) 1202 (75) 
Two or more 262 (25) 129 (25) 391 (25) 
Number of tonic-clonic seizures ever from randomisation to 
achievement of 12-month remission, median (IQR) 
2 (0, 4) 3 (1, 5) 2 (0, 5) 
Age at achievement of 12-month remission (years), 
median (IQR) 
38 (25, 55) 20 (14, 30) 31 (19, 49) 
Time to achieve 12-month remission from randomisation 
(years), median (IQR) 
1.1 (1.0, 1.8) 1.1 (1.0, 1.8) 1.1 (1.0, 1.8) 
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aMost of these patients had focal epilepsy  1 
bMost of these patients were aged < 20 years 2 
Results for multivariable modelling of risk of breakthrough seizure are presented in Table 2. 3 
Univariable results, including the log-rank test p-values, are available in S1 Table. The 4 
multivariable model included three covariates - neurological insult as recorded at 5 
randomisation, total number of tonic-clonic seizures recorded before achieving first period of 6 
12-month remission, and time taken to achieve first period of 12-month remission following 7 
randomisation. Participants with neurological insult were more likely to have a first 8 
breakthrough seizure. Similarly, participants having one or more tonic-clonic seizures ever 9 
before achieving 12-month remission, and taking longer than 12 months to achieve their first 10 
period of 12-month remission were also at an increased risk of a first breakthrough seizure. 11 
The c-statistic for the model was 0.6, indicating that the model accurately discriminates 12 
participants 60% of the time, which is reasonable internal validation.[27, 28] 13 
 14 
Table 2: Multivariable model hazard ratios for time to first breakthrough seizure after a 15 
period of 12-month remission whilst on treatment 16 
Variable Comparison 
Multivariable HR 
(95% CI) 
Neurological insult as recorded at randomisation 
Absent 1.00 
Present 1.55 (1.21, 1.98) 
Total number of tonic-clonic seizures recorded before achieving 
12-month remission 
0 1.00 
1 1.03 (1.02, 1.04) 
2 1.07 (1.04, 1.10) 
3-4 1.10 (1.06, 1.15) 
5-6 1.14 (1.07, 1.20) 
7-10 1.17 (1.09, 1.25) 
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11-20 1.22 (1.12, 1.33) 
>20 1.56 (1.28, 1.90) 
Time taken to achieve 12-month remission following 
randomisation (years) 
1 1.00 
1-1.5 1.27 (1.16, 1.39) 
1.5-2 1.56 (1.32, 1.84) 
2-3 1.74 (1.42, 2.14) 
>3 1.87 (1.49, 2.36) 
HR>1 suggests breakthrough seizure more likely 1 
Italic results are statistically significant 2 
As can be seen in S1 Fig and S1 Table, at two years after achieving 12-month remission 3 
participants without neurological insult, with only one prior tonic-clonic seizure, and achieving 4 
remission immediately at 12 months had a 31% risk of a breakthrough seizure (95% confidence 5 
interval (CI): 28%-35%). Conversely, participants with neurological insult, with 20 prior tonic-6 
clonic seizures and requiring three years to achieve 12-month remission had a 71% risk of a 7 
breakthrough seizure two years after achieving 12-month remission (95% CI: 61%-80%).  8 
Risk of seizure recurrence after a breakthrough seizure 9 
Table 3 summarises the participant demographics for those who have had a first breakthrough 10 
seizure following their first period of 12-month remission.  These participants are consequently 11 
at risk of seizure recurrence, or have a chance of achieving a further period of 12-month 12 
remission. At 2 years following a first breakthrough seizure, the overall risk of a further seizure 13 
is 74% (Fig 3). Participants who were instructed to reduce their dose in the three months prior 14 
to their breakthrough seizure were removed from this analysis, irrespective of whether the 15 
reduction was with the intention to withdraw the drug or not. 16 
Fig 3: Risk of a seizure following a breakthrough seizure 17 
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Table 3: Participant demographics for those at risk of a seizure, or with a chance of 1 
achieving 12-month remission following a first breakthrough seizure, n (%) unless 2 
otherwise stated 3 
Characteristic 
Arm A 
(n=332) 
Arm B 
(n=178) 
Total 
(n=510) 
Male 189 (57) 101 (57) 290 (57) 
Febrile Seizure History 19 (6) 12 (7) 31 (6) 
Epilepsy in first degree relative  29 (9) 38 (21) 67 (13)  
Neurological insult 50 (15) 22 (12) 72 (14) 
Seizures    
Simple/complex Partial + 2° generalised 198 (60) 6 (3) 204 (40) 
Simple or complex partial only 88 (27) 6 (23) 94 (19) 
Generalised tonic-clonic only 7 (1) 54 (30) 61 (12) 
Absence 2 (1) 19 (11) 21 (4) 
Myoclonic/absence + tonic- clonic seizures 2 (10) 44 (25) 46 (9) 
Tonic-clonic (uncertain if focal or generalised) 30 (9) 37 (21) 67 (13) 
Other 5 (2) 12 (7) 17 (3) 
Epilepsy type    
Partial 287 (86) 12 (7) 299 (59) 
Generalised 12 (4) 125 (70) 137 (27) 
Unclassified 33 (10) 41 (23) 74 (14) 
EEG results    
Normal 140 (42) 39 (22) 179 (35) 
Non-specific Abnormality 53 (16) 19 (11) 72 (14) 
Epileptiform Abnormality 105 (32) 116 (65) 221 (43) 
Not donea 34 (10) 4 (2) 38 (8) 
CT/MRI scan results    
Normal 186 (56) 75 (42) 261 (51) 
Abnormal 86 (26) 12 (7) 98 (19) 
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Not doneb 60 (18) 91 (51) 151 (30) 
Drugs attempted to achieve 12-month remission    
One 252 (76) 136 (76) 388 (76) 
Two or more 80 (24) 42 (24) 122 (24) 
Number of tonic-clonic seizures ever until first breakthrough 
seizure, median (IQR) 
2 (0, 6) 3 (2, 6) 3 (1, 6) 
Age at first breakthrough seizure (years), median (IQR) 
40.5 (24.1, 
55.6) 
20.7 (15.1, 
26.3) 
30.9 (19.0, 
49.7) 
Time to achieve 12-month remission from randomisation 
(years), median (IQR) 
1.2 (1.0, 1.9) 1.2 (1.0, 1.8) 1.2 (1.0, 1.8) 
Breakthrough seizure treatment decision    
 No change to treatment plan 189 (59) 107 (63) 296 (60) 
 Increase dosage 124 (39) 62 (36) 186 (38) 
 Decrease dosage (or not specified) 9 (2) 2 (1) 11 (2) 
aMost of these patients had focal epilepsy  1 
bMost of these patients were aged < 20 years 2 
Of the 510 participants included in this analysis, 322 people had a seizure recurrence with 3 
median time to seizure recurrence 30.9 days (IQR 6.5-93.3 days) from the first breakthrough 4 
seizure. Additionally, the median duration of follow-up time after first breakthrough seizure 5 
(following 12-month remission) was 1.6 years (IQR 0.8-2.6 years). The median number of 6 
seizures following the first breakthrough seizure was 1 (IQR 0-7). However, 45% participants 7 
have more than one seizure before re-entering 12-month remission. 8 
Results for multivariable modelling of seizure recurrence after first breakthrough seizure are 9 
presented in Table 4. (Univariable results, including the log-rank test p-values, can be seen in 10 
S3 Table). The multivariable model included three variables – total number of drugs attempted 11 
to achieve initial period of 12-month remission, time to achieve first period of 12-month 12 
remission from randomisation, and treatment decision following first breakthrough seizure. 13 
Participants attempting two or more antiepileptic drugs to achieve first period of 12-month 14 
14 
 
remission were more likely to have a seizure recurrence following a first breakthrough seizure 1 
than those requiring only one drug. Additionally, participants taking longer than one year to 2 
achieve an initial period of 12-month remission were more likely to have a recurrence 3 
following a first breakthrough seizure than those who only took a year. Participants who were 4 
told to increase their dose after their breakthrough seizure also had an increased chance of 5 
seizure recurrence compared to those who do not change their treatment plan. This may indicate 6 
that clinicians were able to identify participants with provoking factors or missed doses of 7 
medication which were the likely cause of the breakthrough seizure. The c-statistic for this 8 
model was 0.6, again showing reasonable internal validation. 9 
Table 4: Effect estimates from multivariable models – risk of seizure recurrence following 10 
first breakthrough seizure (n=510) and likelihood of achieving 12-month remission 11 
following a breakthrough seizure (n=510) 12 
  Multivariable HR (95% CI) 
Variable Comparison 
Seizure recurrence 
post breakthrough 
seizure 
12-month remission 
post breakthrough 
seizure 
Gender 
Female 
N/A 
1.00 
Male 1.34 (1.02, 1.77) 
Drugs attempted to achieve 12-
month remission 
1 1.00 
N/A 
2 or more 1.47 (1.14, 1.91) 
Age at first breakthrough seizure 
(years) 
≤ 20 
N/A 
1.00 
21-30 0.92 (0.86, 0.99) 
31-45 0.87 (0.78, 0.98) 
46-70 0.83 (0.77, 0.97) 
> 70 0.80 (0.66, 0.96) 
Time to achieve 12-month 
remission (years) 
1 1.00 1.00 
1-1.5 1.03 (1.00, 1.06) 0.90 (0.84, 0.95) 
1.5-2 1.08 (1.01, 1.15) 0.72 (0.60, 0.87) 
2-3 1.13 (1.01, 1.26) 0.52 (0.36, 0.76) 
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>3 1.22 (1.02, 1.45) 0.22 (0.09, 0.52) 
Breakthrough seizure decision 
No change to treatment plan 1.00 1.00 
Increase dosage 2.05 (1.63, 2.57) 0.63 (0.47, 0.84) 
Decrease dosage (or not specified) 1.02 (0.58, 1.80) 0.61 (0.32, 1.16) 
HR>1 implies greater chance of seizure recurrence or greater chance of 12-month remission following a breakthrough 1 
seizure as relevant 2 
Italic results are statistically significant 3 
Rates of seizure recurrence predicted by the model at 0.5 and 1 year after a first breakthrough 4 
seizure can be seen in S2 Fig and S4 Table. The data show that treatment decision following 5 
the breakthrough seizure has the biggest effect on risk of recurrence. The effect of number of 6 
drugs attempted to achieve initial period of 12-month remission is noticeable, whilst the time 7 
to achieve inital period of 12-month remission has a smaller effect. 8 
 9 
Chance of achieving 12-month remission after a breakthrough 10 
seizure 11 
Of the 510 participants included in this analysis, 223 people went on to achieve 12-month 12 
remission following a first breakthrough seizure, with median time to seizure recurrence 1.0 13 
years (IQR 1.0-1.6 years). At 2 years following a breakthrough seizure, the overall chance of 14 
re-entering a period of 12-month remission is 64% (Fig 4). 15 
Fig 4: Chance of achieving 12 month remission following a breakthrough seizure 16 
Results for multivariable modelling of chance of 12-month remission following a first 17 
breakthrough seizure are presented in Table 4 (univariable results in S3 Table). The 18 
multivariable model included gender, age at first breakthrough seizure, time to achieve first 19 
period of 12-month remission, and treatment decision following first breakthrough seizure. 20 
According to the model, men are 34% more likely than women to achieve 12-month remission 21 
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after a first breakthrough seizure. Participants achieving their initial period of 12-month 1 
remission immediately after randomisation were more likely to achieve a 12-month remission 2 
after a first breakthrough seizure than those taking longer than one year to achieve remission. 3 
Participants who did not change their dose after their breakthrough seizure were more likely to 4 
achieve a 12-month remission after a first breakthrough seizure than those who increased their 5 
dose. Additionally, participants who were less than or equal to 20 years old were more likely 6 
to have a 12-month remission after a first breakthrough seizure than those aged over 20. The 7 
c-statistic for this model was again 0.6. 8 
The range of likelihoods of achieiving 12-month remission predicted by the model at 1 and 2 9 
years after a first breakthrough seizure are shown in S3 Fig and S5 Table. The data show that 10 
time to achieve initial period of 12-month remission has the biggest effect on chance of 11 
achieving 12-month remission following a first breakthrough seizure. The effect of treatment 12 
decision following the breakthrough seizure is also very clear. The effect of age at acheivement 13 
of initial period of 12-month remission is noticable, whilst gender has a smaller effect. 14 
Discussion 15 
We have shown that several clinical factors influence the risk of a first breakthrough seizure 16 
following an initial period of 12-month remission whilst on treatment, and outcomes following 17 
such a seizure. Of the participants recruited into SANAD, 34% went on to have a first 18 
breakthrough seizure. According to the multivariable model for this outcome, participants with 19 
neurological insult, or with any number of tonic-clonic seizures, or taking over a year to achieve 20 
initial period of 12-month remission were at increased risk of a first breakthrough seizure. 21 
Of those participants who had a first breakthrough seizure, 63% went on to have seizure 22 
recurrence. The factor with the largest effect was antiepileptic drug treatment decision 23 
following the first breakthrough seizure. Those with no change were at much lower risk of a 24 
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further seizure than those with a treatment increase. This might at first appear counterintuitive, 1 
but it may indicate that clinicians are able to identify seizures occurring as a result of participant 2 
non-adherence.  Alternative reasons may include the presence of other lifestyle factors 3 
associated with increased seizure risk. The appropriate management for this perceived non-4 
adherence is to recommend adherence with no dose change, or avoidance of other seizure 5 
provoking factors. However the clinician may not be aware of the presence of this non-6 
adherence or provoking factors and may resultantly increase the antiepileptic drug dosage – a 7 
dose increase is usually indicated for those with a breakthrough seizure despite adhering to 8 
treatment and with no other seizure provoking factors. Other risk factors for this outcome were 9 
number of drugs required to achieve initial period of 12-month remission, and time to achieve 10 
first period of 12-month remission - participants requiring polytherapy to achieve first period 11 
of 12-month remission and taking longer than one year to achieve it were more likely to have 12 
a recurrence.  13 
Of participants who had a first breakthrough seizure, 44% went on to achieve another period 14 
of 12-month remission. Male participants, participants aged under 20 years, and participants 15 
achieving their first period of 12-month remission immediately at one year after randomisation 16 
were significantly more likely to achieve 12-month remission following a first breakthrough 17 
seizure. This gender effect was also observed for the primary outcomes in the SANAD trial, 18 
whereby men were more likely to achieve an initial period of 12-month remission.[29] This 19 
effect remains unexplained, and might have a biological explanation, or may be because men 20 
might be less likely to report seizures in order to minimise impact on their employment or 21 
driving license. Participants with no recommended antiepileptic drug treatment change after a 22 
first breakthrough seizure were also more likely to achieve 12-month remission than those who 23 
increased their dose, indicating (as discussed above) that clinicians might be able to identify 24 
those with seizures due to provoking factors requiring no dose change. 25 
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Our model for risk of a first breakthrough seizure is the first known analysis of risk factors for 1 
a first breakthrough seizure in developed countries. However, the results are broadly in line 2 
with those published considering risk factors for treatment failure following randomisation to 3 
the SANAD study.[30, 31] The Arm A multivariable model focussed on participants with focal 4 
epilepsy and included variables for gender, treatment history, age, total number of seizures 5 
prior to randomisation, EEG result, seizure type, focal epilepsy site of onset, and randomised 6 
treatment. Of these, only number of tonic-clonic seizures was in common with the model 7 
presented in this paper. The Arm B multivariable model focussed on participants with 8 
generalised and unclassified epilepsy and included variables for treatment history, EEG result, 9 
seizure type, and randomised treatment.  10 
Previous work also considered risk of second treatment failure after a first and the likelihood 11 
of achieving 12-month remission following a treatment failure.[32] The multivariable model 12 
for second treatment failure included covariates for total number of tonic-clonic seizures before 13 
first treatment failure, reasons for treatment failure, and CT/MRI scan result. The multivariable 14 
model for likelihood of achieving 12-month remission following a treatment failure included 15 
covariates for gender, age, time on randomised treatment at first treatment failure, neurological 16 
insult, total number of tonic-clonic seizure before first treatment failure, reason for treatment 17 
failure, seizure type, and CT/MRI scan result.[32]  18 
Limitations 19 
Pragmatic clinical trials usually recruit a heterogeneous group of participants. Although some 20 
have criticised this approach [33, 34] the strength of this method has been highlighted here as 21 
it allows an investigation of sources of heterogeneity of outcome. Other limitations of SANAD 22 
have been discussed elsewhere.[29]  23 
19 
 
EEG was not included in the final model which was selected based on statistical model 1 
selection methods.  However, EEG was undertaken at randomisation rather than at the time of 2 
the breakthrough seizure – measuring EEG at time of breakthrough would have significant 3 
resource implications for health services.  Additionally, adherence was not measured and 4 
therefore could not be included in the list of covariates for possible inclusion in any model. 5 
However, no affordable methods exist at present to measure adherence in long-term pragmatic 6 
publically funded trials. 7 
Due to the definition of each end point - particularly the post breakthrough seizure endpoints - 8 
the sample size is relatively small. Additionally, due to the extended follow-up period required 9 
to observe participants having events of interest, the duration of follow-up after a first 10 
breakthrough is quite limited. These two factors potentially reduce the power of the analyses 11 
and could mean that some significant results are not identified.  12 
This manuscript has presented a number of models that can further inform participant 13 
counselling and potentially treatment decision making. However, these models require 14 
validation in other similar datasets. The predictive power of each model also needs to be 15 
explored. SANAD II is currently underway. In the meantime there are no other datasets that 16 
are similar to SANAD. The closest match is a set of individual participant data collected by the 17 
authors.[35] This data is however missing important covariates. Internal validation of the 18 
models presented here suggests reasonable model fit however. 19 
Conclusions 20 
This is the first analysis to consider the risk of a breakthrough seizure and outcomes following 21 
a breakthrough seizure, in participants from a developed country. The SANAD Study is 22 
currently the largest and longest study of participants with newly diagnosed epilepsy and 23 
therefore provides the best evidence for this work. 24 
20 
 
Participants taking a long time to achieve first period of 12-month remission, and having a 1 
large number of seizures, are the most likely to have a first breakthrough seizure. However 2 
once a first breakthrough seizure has occurred only time to achieve initial period of 12-month 3 
remission continues to be important. Instead, number of drugs required to achieve initial period 4 
of remission, gender and age are found to be associated with the outcomes. Therefore, a focus 5 
on achieving 12-month remission swiftly represents the best therapeutic aim to reduce the risk 6 
of a first breakthrough seizure and subsequent negative outcomes. 7 
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